Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.
about
Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@en
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@nl
type
label
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@en
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@nl
prefLabel
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@en
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@nl
P2860
P1476
Evaluation of WO2012037204 and ...... asis of a US$251 million deal.
@en
P2093
Peter Norman
P2860
P304
P356
10.1517/13543776.2012.701282
P407
P577
2012-07-06T00:00:00Z